Builders Risk Exclusions for Pharmaceutical Manufacturers

Understanding what Builders Risk does NOT cover for Pharmaceutical Manufacturers

Pharmaceutical Manufacturers purchasing Builders Risk should expect 15-30 exclusions in the policy form. Most are routine and unremarkable. A small subset — typically 3-5 trade-specific exclusions — matters operationally and should be reviewed carefully before binding.

For manufacturer, the meaningful exclusions usually target the riskiest aspects of the operation: the activities most likely to produce claims, where the carrier wants either explicit exclusion or buy-back endorsements at additional premium.

Pollution-related exclusions on Pharmaceutical Manufacturers Builders Risk

The total pollution exclusion on most commercial general liability and adjacent Builders Risk policies removes coverage for pollution-related losses. For Pharmaceutical Manufacturers with any meaningful environmental exposure — fuel handling, chemical use, waste generation, hazardous materials — this exclusion can be operationally significant.

The fix is usually a dedicated pollution liability policy, sometimes endorsed onto the existing Builders Risk via a pollution buy-back. The cost varies by exposure but typically adds 5-15% to the base Builders Risk cost for modest exposures, more for material ones.

How the "professional services" exclusion affects Pharmaceutical Manufacturers Builders Risk

Professional services exclusions affect Pharmaceutical Manufacturers more than most realize. The exclusion can apply to: design recommendations on a project, technical specifications a pharmaceutical manufacturer provides, consulting on system selection, or supervisory advice given to a customer or sub.

For most Pharmaceutical Manufacturers, the practical answer is dedicated professional liability coverage at $1M-$5M alongside the Builders Risk policy. The annual premium is usually modest relative to the exposure it covers.

How contracts and Builders Risk exclusions interact for Pharmaceutical Manufacturers

Most Builders Risk policies exclude contractual liability — losses arising solely from contract obligations the pharmaceutical manufacturer has assumed. There is usually an exception for "insured contracts," which preserves coverage for liability assumed in standard commercial agreements (leases, sidetrack agreements, indemnity in railroad-easement contracts, etc.).

For Pharmaceutical Manufacturers, this matters when contracts contain indemnity clauses that exceed what the policy's insured-contract exception covers. A broad indemnity in a vendor contract could create exposure the Builders Risk policy won't respond to. Reviewing contract indemnity language against policy exceptions before signing is the standard practice.

The intentional-acts firewall in Pharmaceutical Manufacturers Builders Risk

The intentional-acts exclusion on Pharmaceutical Manufacturers Builders Risk is rarely a problem for legitimate business activity. The exclusion targets situations the carrier won't insure regardless of intent: criminal acts, fraud, deliberate property damage. Routine commercial operations don't trigger it.

Where the exclusion gets murky: dispute scenarios where one party characterizes the other's actions as intentional. Carriers usually defer to the courts on intent determinations, but a coverage dispute can develop while the underlying claim is pending.

Common claim-denial scenarios on Pharmaceutical Manufacturers Builders Risk

Pharmaceutical Manufacturers Builders Risk claims most often face denials in three predictable scenarios: pollution-related losses denied under the total pollution exclusion, professional-services claims denied where advisory work is involved, and contractual-assumption losses denied for indemnities beyond the insured-contract exception.

The pattern: the claim itself looks covered, but a component of the loss triggers an exclusion. The carrier denies based on the triggered exclusion; the pharmaceutical manufacturer disputes the denial. Resolution often requires either negotiating coverage or pursuing the claim through bad-faith or coverage litigation.

The pre-bind exclusion review on Pharmaceutical Manufacturers Builders Risk

Pharmaceutical Manufacturers who buy Builders Risk without reading the exclusion list are taking on hidden exposure. The exclusions are not obscure — they are in the policy form — but they require deliberate review to surface. The broker's job is to walk through them; the pharmaceutical manufacturer's job is to engage with the review.

Set aside 30 minutes per renewal for the exclusion review. Most reviews flag 1-3 exclusions worth discussing; most discussions lead to either acceptance, buy-back, or shopping to a different carrier with different exclusions. All three outcomes are better than discovering the exclusion at claim time.